HTB

CROI 2021 (virtual)

Featured CROI 2021: First results using capsid inhibitor lenacapavir against MDR HIV: potential for six-monthly ART and PrEP

CROI 2021: Pregnancy outcomes and weight gain with dolutegravir and TAF

CROI 2021: New compounds for prevention and treatment of COVID-19

Oral molnupiravir at higher dose reduces SARS-CoV-2 viral load at day five in small phase 2 study

Bamlanivimab prophylaxis reduces hospitalisation and mortality: results from phase 3 BLAZE-2 study

Dual Eli-Lilly mAb bamlanivimab and etesevimab reduces hospitalisation after single infusion: results from BLAZE-1 study

Dual Regeneron mAbs casirivimab with imdevimab reduce transmission: interim results from phase 3 study

CROI 2021: Presentations from the LEAP workshop 2021

CROI 2021: Presentations on NATAP.org

28th Conference on Retroviruses and Opportunistic Infections (CROI 2021)

CROI 2021: Urgency of global access to vaccines, the potential of mAbs and the lessons learned from HIV

CROI 2021: Community challenge 6-month CROI pay wall – rather than usual open access…

CROI 2021: Once-daily GSK254 maturation inhibitor as treatment for HIV multidrug resistance

CROI 2021: Dosing for once-weekly oral ART: islatravir plus MK-8507 studies due to start in 2021

CROI 2021: Islatravir dosing for once-monthly and annual PrEP: if effective this could end HIV transmission

CROI 2021: Dolutegravir with recycled tenofovir and lamivudine performs well second-line: primary results from the NADIA trial

CROI 2021: HIV capsid uncoats in the CD4 nucleus rather than the cytoplasm – viral lifecycle updated…

CROI 2021: Community HIV cure workshops online